Jun Abe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jun Abe has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Hirohisa Saito
Tokyo, Japan
4 shared publications Seiji Noma
Hachiouji Metropolitan Children’s Hospital , Tokyo
3 shared publicationsMasaru Terai
2 shared publicationsTakao Kohsaka
Department of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan
2 shared publicationsToshiaki Jibiki
2 shared publicationsYasuhiko Ito
Department of Allergy and Immunology, National Research Institute for Child Health and Development, Tokyo, Japan
2 shared publications
Latest Publications
- 1 November 2008
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 122 (5) , 1008-1013.e8
Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease
- 1 November 2008
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 122 (5) , 1008-1013.e8
Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease
- 1 May 2005
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 174 (9) , 5837-5845
Gene Expression Profiling of the Effect of High-Dose Intravenous Ig in Patients with Kawasaki Disease
Kawasaki disease (KD) is an acute vasculitis of infants and young children, preferentially affecting the coronary arteries. Intravenous infusion of high dose Ig (IVIG) effectively reduces systemic inflammation and prevents coronary artery lesions in KD. To investigate the mechanisms underlying the therapeutic effects of IVIG, we examined gene expression profiles of PBMC and purified monocytes obtained from acute patients before and after IVIG therapy. The results suggest that IVIG suppresses activated monocytes and macrophages by altering various functional aspects of the genes of KD patients. Among the 18 commonly decreased transcripts in both PBMC and purified monocytes, we selected six genes, FCGR1A, FCGR3A, CCR2, ADM, S100A9, and S100A12, and confirmed the microarray results by real-time RT-PCR. Moreover, the expressions of FcγRI and FcγRIII on monocytes were reduced after IVIG. Plasma S100A8/A9 heterocomplex, but not S100A9, levels were elevated in patients with acute KD compared with those in febrile controls. Furthermore, S100A8/A9 was rapidly down-regulated in response to IVIG therapy. Persistent elevation of S100A8/A9 after IVIG was found in patients who later developed coronary aneurysms. These results indicate that the effects of IVIG in KD may be mediated by suppression of an array of immune activation genes in monocytes, including those activating FcγRs and the S100A8/A9 heterocomplex.
- 1 May 2005
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 174 (9) , 5837-5845
Gene Expression Profiling of the Effect of High-Dose Intravenous Ig in Patients with Kawasaki Disease
Kawasaki disease (KD) is an acute vasculitis of infants and young children, preferentially affecting the coronary arteries. Intravenous infusion of high dose Ig (IVIG) effectively reduces systemic inflammation and prevents coronary artery lesions in KD. To investigate the mechanisms underlying the therapeutic effects of IVIG, we examined gene expression profiles of PBMC and purified monocytes obtained from acute patients before and after IVIG therapy. The results suggest that IVIG suppresses activated monocytes and macrophages by altering various functional aspects of the genes of KD patients. Among the 18 commonly decreased transcripts in both PBMC and purified monocytes, we selected six genes, FCGR1A, FCGR3A, CCR2, ADM, S100A9, and S100A12, and confirmed the microarray results by real-time RT-PCR. Moreover, the expressions of FcγRI and FcγRIII on monocytes were reduced after IVIG. Plasma S100A8/A9 heterocomplex, but not S100A9, levels were elevated in patients with acute KD compared with those in febrile controls. Furthermore, S100A8/A9 was rapidly down-regulated in response to IVIG therapy. Persistent elevation of S100A8/A9 after IVIG was found in patients who later developed coronary aneurysms. These results indicate that the effects of IVIG in KD may be mediated by suppression of an array of immune activation genes in monocytes, including those activating FcγRs and the S100A8/A9 heterocomplex.
- 1 February 2004
- Published by Elsevier in Clinical Immunology
- Vol. 110 (2) , 159-171
Critical role of T cell migration in bacterial superantigen-mediated shock in mice
- 1 February 2004
- Published by Elsevier in Clinical Immunology
- Vol. 110 (2) , 159-171
Critical role of T cell migration in bacterial superantigen-mediated shock in mice
- 1 January 2003
- Published by Springer Nature in Pediatric Research
- Vol. 53 (1) , 171
Adrenomedullin mRNA is Highly Expressed in PBMC of Acute Kawasaki Syndrome
- 1 January 2003
- Published by Springer Nature in Pediatric Research
- Vol. 53 (1) , 171
Adrenomedullin mRNA is Highly Expressed in PBMC of Acute Kawasaki Syndrome
- 1 January 2003
- Published by Springer Nature in Pediatric Research
- Vol. 53 (1) , 168
Colonization of the Superantigen-producing Staphylococcus aureus among Patients with Kawasaki Disease
- 1 January 2003
- Published by Springer Nature in Pediatric Research
- Vol. 53 (1) , 168
Colonization of the Superantigen-producing Staphylococcus aureus among Patients with Kawasaki Disease
- Open Access
- 1 February 2000
- Published by Wiley in Microbiology and Immunology
- Vol. 44 (2) , 79-88
Characterization and Distribution of a New Enterotoxin‐Related Superantigen Produced by Staphylococcus aureus
Staphylococcal enterotoxins (SEs) are a family of structurally related pyrogenic exotoxins consisting of the five prototypic SEs (types A to E) and three newly characterized SEs (types G to I) produced by Staphylococcus aureus (S. aureus). They also work as superantigens and cause food poisoning and shock symptoms in humans. In this study, we cloned a new variant gene of the seg and characterized its superantigenic properties and distribution among the clinical isolates of S. aureus. The gene encodes a 233 amino acid protein which is highly homologous to SEG (97.7%). The variant SEG (SEGv) expressed by the cloned gene exerted mitogenic activity on human peripheral blood mononuclear cells at the concentration of 100 pg/ml. T cells bearing Vβ3, 12, 13.1, 13.2, 14 and 15 were preferentially expanded after stimulation with the recombinant protein. The mRNA of the variant seg gene was detected in the total RNA of the organisms bearing this gene. By PCR, 27 out of 48 clinical isolates of S. aureus (56%) possessed either the seg or variant seg gene. These findings suggest that SEG, or SEGv, is one of the most frequently produced superantigen exotoxins by S. aureus and may participate in the inflammatory process of the host by activating a distinct set of Vβ families of T cells.
- 1 February 2000
- Published by Wiley in Microbiology and Immunology
- Vol. 44 (2) , 79-88
Open AccessCharacterization and Distribution of a New Enterotoxin‐Related Superantigen Produced by Staphylococcus aureus
Staphylococcal enterotoxins (SEs) are a family of structurally related pyrogenic exotoxins consisting of the five prototypic SEs (types A to E) and three newly characterized SEs (types G to I) produced by Staphylococcus aureus (S. aureus). They also work as superantigens and cause food poisoning and shock symptoms in humans. In this study, we cloned a new variant gene of the seg and characterized its superantigenic properties and distribution among the clinical isolates of S. aureus. The gene encodes a 233 amino acid protein which is highly homologous to SEG (97.7%). The variant SEG (SEGv) expressed by the cloned gene exerted mitogenic activity on human peripheral blood mononuclear cells at the concentration of 100 pg/ml. T cells bearing Vβ3, 12, 13.1, 13.2, 14 and 15 were preferentially expanded after stimulation with the recombinant protein. The mRNA of the variant seg gene was detected in the total RNA of the organisms bearing this gene. By PCR, 27 out of 48 clinical isolates of S. aureus (56%) possessed either the seg or variant seg gene. These findings suggest that SEG, or SEGv, is one of the most frequently produced superantigen exotoxins by S. aureus and may participate in the inflammatory process of the host by activating a distinct set of Vβ families of T cells.
- Open Access
- 15 April 1997
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 99 (8) , 1823-1830
Clinical role for a superantigen in Yersinia pseudotuberculosis infection.
Yersinia pseudotuberculosis is an enteric pathogen that causes a variety of clinical symptoms in the human. Recently, we reported the production of a superantigen (Y. pseudotuberculosis-derived mitogen, YPM) by this organism and characterized the gene structure of ypm. To further study the potential pathogenic role of YPM in Y. pseudotuberculosis infection, we assayed IgG anti-YPM antibodies and T cell antigen receptor-Vbeta expression of the T cells in peripheral blood and in mesenteric lymph node in patients acutely infected with Y. pseudotuberculosis. 20 out of 33 patients (61%) had an elevated antibody titer compared with healthy controls (P = 0.0001). Patients with systemic symptoms such as lymphadenopathy, transient renal dysfunction, and arthritis had significantly higher titers of anti-YPM than patients with gastrointestinal tract symptoms alone. T cells bearing the Vbeta3 gene segment were significantly increased (P = 0.009) among acute phase patients compared with healthy children. During the convalescence phase of the illness, there was a reduction in the abnormal level of Vbeta3 T cells. Moreover, in the mesenteric lymph node, an elevated level of Vbeta3 T cells compared with peripheral blood and a sequence diversity in the junctional region of the T cell antigen receptor beta-chain containing Vbeta3 element was observed in one patient. Together, these findings suggest that YPM was produced in vivo and played an important role in the pathogenesis of Y. pseudotuberculosis infection.
- 15 April 1997
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 99 (8) , 1823-1830
Open AccessClinical role for a superantigen in Yersinia pseudotuberculosis infection.
Yersinia pseudotuberculosis is an enteric pathogen that causes a variety of clinical symptoms in the human. Recently, we reported the production of a superantigen (Y. pseudotuberculosis-derived mitogen, YPM) by this organism and characterized the gene structure of ypm. To further study the potential pathogenic role of YPM in Y. pseudotuberculosis infection, we assayed IgG anti-YPM antibodies and T cell antigen receptor-Vbeta expression of the T cells in peripheral blood and in mesenteric lymph node in patients acutely infected with Y. pseudotuberculosis. 20 out of 33 patients (61%) had an elevated antibody titer compared with healthy controls (P = 0.0001). Patients with systemic symptoms such as lymphadenopathy, transient renal dysfunction, and arthritis had significantly higher titers of anti-YPM than patients with gastrointestinal tract symptoms alone. T cells bearing the Vbeta3 gene segment were significantly increased (P = 0.009) among acute phase patients compared with healthy children. During the convalescence phase of the illness, there was a reduction in the abnormal level of Vbeta3 T cells. Moreover, in the mesenteric lymph node, an elevated level of Vbeta3 T cells compared with peripheral blood and a sequence diversity in the junctional region of the T cell antigen receptor beta-chain containing Vbeta3 element was observed in one patient. Together, these findings suggest that YPM was produced in vivo and played an important role in the pathogenesis of Y. pseudotuberculosis infection.